Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
AUTLAutolus
5assets
Autolus
- obe-celobecabtagene autoleucel / AUCATZYL / CD19 / autologous CAR T cell therapy / Oncology; Autoimmune diseaseB-NHLPhase 1enrollingPediatric B-ALL & B-NHLPhase 1enrollingPCNSLPhase 1enrolling
- AUTO1/22CD19; CD22 / autologous CAR T cell therapy / OncologyPediatric ALLPhase 1enrolling
- AUTO4TRBC1 / autologous CAR T cell therapy / OncologyPTCLPhase 1enrolling
- AUTO6NGGD2 / autologous CAR T cell therapy / OncologyNeuroblastoma; other tumor typesPhase 1enrolling
- AUTO8BCMA; CD19 / autologous CAR T cell therapy / OncologyMultiple myelomaPhase 1enrolling